Related Experiment Video
Updated: Feb 24, 2026

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
Published on: February 25, 2021
Limitations in Clinical Translation of Nanoparticle-Based Gene Therapy
Joanna K L Wong1, Rashin Mohseni2, Amir Ali Hamidieh2
1School of Medicine, Imperial College London, London, UK.
Abstract:
Organic nanoparticle-based (ONP) gene therapy is a potential strategy to cure human cancer. However, there are still many practical barriers before the promising results from in vitro and preclinical studies can be translated to clinical success. We discuss the reasons behind the hesitant uptake by the clinic.
Insights
Organic nanoparticle-based (ONP) gene therapy shows promise for cancer treatment. However, significant practical challenges hinder its clinical application, despite positive preclinical results.
Area of Science:
- Oncology
- Nanotechnology
- Gene Therapy
Background:
- Organic nanoparticle-based (ONP) gene therapy presents a novel approach for cancer treatment.
- Promising in vitro and preclinical data suggest significant therapeutic potential.
Discussion:
- Clinical translation of ONP gene therapy faces numerous practical barriers.
- Hesitancy in clinical adoption stems from challenges in scalability, safety, and regulatory pathways.
Key Insights:
- Understanding the specific hurdles is crucial for advancing ONP gene therapy.
- Bridging the gap between preclinical success and clinical reality requires targeted solutions.
Outlook:
- Overcoming current limitations is essential for realizing the full potential of ONP gene therapy in oncology.
- Future research should focus on addressing practical challenges to facilitate clinical integration.
More Related Videos
Related Concept Videos
Gene Therapy
Microorganisms in Medicine and Therapeutics

